PR Newswire Clinical TrialsOriginal article
Cell Stem Cell: Die tBE-vermittelte Base-Editing-Therapie erzielt bei unterschiedlichen genetischen Hintergründen eine dauerhafte klinische Remission bei Sichelzellkrankheit und β-Thalassämie
Data ReadoutpositivetBEPositive
AI Analysis
Summary
A new study confirms that tBE base-editing therapy achieves sustained clinical remission and transfusion independence in sickle cell disease and beta-thalassemia patients across diverse genetic backgrounds, including African and Asian populations.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
tBE-mediated base editing therapy achieved sustained clinical remission in sickle cell disease and beta-thalassemia patients across different genetic backgrounds including African SCD patients and South/Southeast Asian TDT patients
Importance:7/10
Sentiment:
0.85
Gene TherapyBase EditingSickle Cell DiseaseBeta-ThalassemiaClinical DataTransfusion Independence
Read the original article
Published by PR Newswire Clinical Trials on September 8, 2026 4:52 PM